The Huffington Post India [6 June, 2017]
“How the introduction of a new drug in India will greatly help children living with HIV”
New Delhi, India – 6 June 2017
On 25 May, an expert committee of the Central Drugs Standard Control Organization (CDSCO), the Indian drug regulatory authority, finally permitted the child-friendly and heat-stable pellet formulation of the HIV drug lopinavir/ritonavir (LPV/r) to be registered. This has opened up crucial supplies from Cipla to the Indian National AIDS Control Programme (NACO), which had up to now been struggling to source quality assured paediatric formulations of the drug.
Takeda [1 June, 2017]
“グローバルヘルス技術振興基金第二期への資金拠出について” – “Financial contribution to the second phase of GHIT”
Business Daily [30 May, 2017]
“Crossing fingers for child-friendly ARVs”
Scroll.in [24 May, 2017]
“A new paediatric HIV drug has been stuck for months without the drug regulator’s approval”
by Giralt AN, Nöstlinger C, Lee J, Salami O, Lallemant M, Ouma O, Nyamongo I, Marchal B.
BMJ Open, March 2017
Reuters [21 April, 2017]
“Progress in fighting tropical diseases but funding and conflicts pose challenges”
Radio Okapi [20 April, 2017]
“RDC: des efforts sont nécessaires pour éliminer les maladies tropicales négligées” – “DRC: efforts needed to eliminate neglected tropical diseases”
Devex [20 April, 2017]
“Commitments made on neglected tropical diseases at WHO summit”
Le Temps [19 April, 2017]
“Des progrès dans la lutte contre les maladies tropicales négligées” – “Progress in addressing neglected tropical diseases”
Le Monde [19 April, 2017]
“Mobilisation contre les maladies tropicales négligées” – “Mobilization against neglected tropical diseases”
Devex [18 April, 2017]
“Strides in progress on neglected tropical diseases as global partners meet”
October 24-26, 2017
Janice Lee, Project Manager Paediatric HIV/HCV, DNDi presented on the paediatric HIV RELIVING Study.
Financial Times [18 April, 2017]
“The long road to elimination of neglected tropical diseases”
[Tokyo, Japan – March 30, 2017]
Daiichi Sankyo announces collaborative research on drugs for neglected diseases
Daiichi Sankyo Company, Limited (hereafter, “Daiichi Sankyo”), announced that it has entered into a new joint research agreement with the Drugs for Neglected Diseases initiative (hereafter, “DNDi”) with regard to a new research program, the Hit-to-Lead Project, with the aim to develop drug treatments for two neglected tropical diseases, leishmaniasis and Chagas disease.
[Seattle, USA – February 14, 2017]
Landmark study proves that “super-boosting” approach counters negative interaction between key HIV and TB drugs
The non-profit research and development organization Drugs for Neglected Diseases initiative (DNDi) has released results of a study in South Africa that will make it easier for healthcare workers to treat children living with HIV who are co-infected with tuberculosis.
October 4-6, 2017
Graeme Bilbe, R&D Director, DNDi and Suman Rijal, Director of DNDi Regional Office India took part in the event.
September 26-29, 2017
DNDi Latin America’s Regional Policy Advocacy Consultant, Francisco Viegas, gave a presentation on innovation and access for neglected populations.
Action on Antibiotic Resistance (ReAct) Africa Annual Conference 2017
September 18-19, 2017
DNDi Africa’s Director, Monique Wasunna, gave a presentation on DNDi‘s various programme models.